LGND - Ligand Pharmaceuticals, Inc. - Ordinary Shares - Class B
IEX Last Trade
105.63
-0.230 -0.218%
Share volume: 113,893
Last Updated: Fri 30 Aug 2024 10:00:00 PM CEST
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
0.87%
PREVIOUS CLOSE
CHG
CHG%
$105.86
-0.23
-0.22%
View ratios
| Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
| Report Date | 2022-08-09 | 2022-11-08 | 2023-02-28 | 2023-05-08 | 2023-08-09 | 2023-11-09 | 2024-02-29 | 2024-05-08 | |
| Assets | |||||||||
| Total Assets | 1.076 B | 1.051 B | 762.668 M | 811.076 M | 758.105 M | 769.226 M | 787.216 M | 913.869 M | |
| Current Assets | 243.784 M | 220.432 M | 263.601 M | 328.195 M | 276.711 M | 253.994 M | 237.429 M | 368.913 M | |
| Inventories | 24.773 M | 22.326 M | 13.294 M | 14.011 M | 26.906 M | 25.392 M | 23.969 M | 21.337 M | |
| Other Current Assets | 7.804 M | 10.746 M | 3.399 M | 2.331 M | 2.770 M | 2.097 M | 3.839 M | 8.548 M | |
| Short Term Investments | 7.804 M | 10.746 M | 3.399 M | 2.331 M | 2.770 M | 2.097 M | 3.839 M | 8.548 M | |
| Total Receivables | 63.272 M | 65.953 M | 35.038 M | 29.188 M | 27.994 M | 36.003 M | 39.312 M | 28.435 M | |
| Current Cash | 147.935 M | 121.407 M | 211.870 M | 282.665 M | 219.041 M | 190.502 M | 170.309 M | 310.593 M | |
| Total Non-current Assets | 832.504 M | 830.173 M | 499.067 M | 482.881 M | 481.394 M | 515.232 M | 549.787 M | 544.956 M | |
| Property Plant Equipment | 30.954 M | 33.418 M | 12.482 M | 11.743 M | 11.382 M | 16.178 M | 15.607 M | 15.135 M | |
| Other Assets | 21.348 M | 20.723 M | 8.831 M | 8.577 M | 8.257 M | 11.992 M | 9.316 M | 80.154 M | |
| Intangible Assets | 538.631 M | 527.218 M | 352.637 M | 344.347 M | 336.160 M | 321.445 M | 366.897 M | 291.420 M | |
| Goodwill | 181.206 M | 181.206 M | 105.673 M | 105.673 M | 105.673 M | 103.770 M | 103.370 M | 105.250 M | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 1.076 B | 1.051 B | 762.668 M | 811.076 M | 758.105 M | 769.226 M | 787.216 M | 913.869 M | |
| Total liabilities | 273.923 M | 234.307 M | 165.183 M | 164.759 M | 93.213 M | 101.330 M | 86.303 M | 107.348 M | |
| Total current liabilities | 167.853 M | 135.241 M | 98.810 M | 98.929 M | 29.388 M | 15.727 M | 16.782 M | 17.818 M | |
| Accounts Payable | 19.153 M | 15.887 M | 5.307 M | 6.135 M | 9.582 M | 2.475 M | 2.427 M | 1.893 M | |
| Other liabilities | 36.313 M | 34.341 M | 25.422 M | 24.637 M | 25.169 M | 47.185 M | 32.144 M | 33.733 M | |
| Current long term debt | 115.024 M | 76.648 M | 76.740 M | 76.833 M | 0.000 | 0.000 | 7.000 K | 3.000 K | |
| Long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other liabilities | 36.313 M | 34.341 M | 25.422 M | 24.637 M | 25.169 M | 47.185 M | 32.144 M | 33.733 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 802.365 M | 816.298 M | 597.485 M | 646.317 M | 664.892 M | 667.896 M | 700.913 M | 806.521 M | |
| Common stock | 16.868 M | 16.888 M | 16.892 M | 17.063 M | 17.276 M | 17.380 M | 17.473 M | 17.732 M | |
| Retained earnings | 467.943 M | 468.347 M | 450.862 M | 492.811 M | 495.101 M | 484.828 M | 503.016 M | 589.155 M |